All In Biotech

Drug Trial Radar · NCT05756153

A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Last checked: Nov 19, 2026Latest source record: Aug 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

47

Actual

Start

Apr 25, 2023

Primary completion

Apr 30, 2025

Study completion Apr 30, 2025

Sponsor

Sponsor type
Industry
First posted
Mar 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase Ib/II study. The objectives are to evaluate the safety/tolerability and efficacy of GFH925 in combination with Cetuximab in advanced KRAS G12C mutant NSCLC, to characterize pharmacokinetics (PK) of GFH925 in combination with Cetuximab in advanced KRAS G12C mutant NSCLC

Conditions

  • Advance Non-small Cell Lung Cancer

Interventions

  • GFH925Drug

    GFH925 tablets administered orally daily.

  • CetuximabDrug

    Cetuximab administered intravenously Q2W.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib: adverse eventsTime frame: 28 days
  2. Phase II: objective response rateTime frame: up to 1 year after last patient in

Locations

21 sites in 3 countries. Site status is shown where the registry gives one.

  • General Hospital of Athens "Alexandra"

    Athens, Greece

  • University General Hospital "Attikon"

    Athens, Greece

  • Bioclinic Thessaloniki

    Thessaloniki, Greece

  • University General Hospital "Attikon"

    Athens, Haidari, Greece

  • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS

    Bologna, Emilia-Romagna, Italy

  • IRCCS Centro di Riferimento Oncologico

    Aviano, Friuli Venezia Giulia, Italy

  • IOV - Istituto Oncologico Veneto IRCCS

    Padova, Friuli Venezia Giulia, Italy

  • Istituto Nazionale Tumori Regina Elena IRCCS

    Rome, Lazio, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Lombardy, Italy

  • Candiolo Cancer Institute, FPO-IRCCS

    Candiolo, Piedmont, Italy

  • A.O.U. Senese Policlinico Santa Maria alle Scotte

    Siena, Tuscany, Italy

  • Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Roma)

    Verona, Veneto, Italy

  • Hospital Universitari Dexeus,Servicio de Oncologia Medica

    Barcelona, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

  • Clinica Mi Tres Torres

    Barcelona, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Regional Universitario de Malaga,Oncology Dept

    Málaga, Spain

  • Virgen del Rocio University Hospital

    Seville, Spain

  • Instituto Valenciano de Oncologia IVO,Servicio de Oncologia Medica

    Valencia, Spain

  • ICO Badalona - Hospital Universitari Germans Trias i Pujol,Servicio de Oncologia Medica

    Badalona, Barcelona, Spain

  • Clinica Universidad de Navarra, Servicio de Oncologia

    Pamplona, Navarre, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.